Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Portfolio Pulse from Vandana Singh
Moderna and Pfizer have announced that their updated COVID-19 vaccines show effectiveness against the 'Eris' variant in early human and preclinical studies. Moderna's vaccine showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants, suggesting it may effectively target the expected circulating variants of COVID-19 in the upcoming vaccination season. Pfizer's updated COVID-19 shot also showed neutralizing activity against the 'Eris' subvariant in a study conducted on mice. Both companies have submitted their updated vaccines to the FDA and other regulators.
August 18, 2023 | 11:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech, Pfizer's partner, has created versions of their shots aimed at the XBB.1.5 subvariant, indicating their continued collaboration and adaptability to new COVID-19 variants.
The news of BioNTech and Pfizer's continued collaboration and their adaptability to new COVID-19 variants is directly relevant to BioNTech and could potentially boost its stock.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Moderna's updated COVID-19 vaccine shows effectiveness against the 'Eris' variant, potentially boosting its relevance in the upcoming vaccination season.
The news of Moderna's vaccine showing effectiveness against the 'Eris' variant is directly relevant to the company and could potentially boost its stock as it indicates the company's ability to adapt to new variants of the virus.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Pfizer's updated COVID-19 shot showed neutralizing activity against the 'Eris' subvariant in a study conducted on mice, indicating potential effectiveness against this variant.
The news of Pfizer's updated COVID-19 shot showing effectiveness against the 'Eris' subvariant is directly relevant to the company and could potentially boost its stock as it indicates the company's ability to adapt to new variants of the virus.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100